<DOC>
	<DOC>NCT01652716</DOC>
	<brief_summary>To compare the effect on glycemic control (HbA1c) of exenatide suspension administered once weekly to that achieved by exenatide administered twice daily for 28 weeks in subjects with type 2 diabetes mellitus. To examine the long-term (52 weeks of treatment) safety and effect on glucose control of exenatide suspension administered once weekly in subjects with type 2 diabetes mellitus.</brief_summary>
	<brief_title>Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>At least 18 years old Diagnosed with type 2 diabetes mellitus HbA1c 7.1 to 11%, inclusive, at screening Fasting plasma glucose &lt;280 mg/dL (15.5 mmol/L) Body mass index (BMI) &lt;=45 kg/m2, inclusive, at screening Treated with diet and exercise or a stable regimen of metformin, sulfonylurea, pioglitazone or any 2 of these agents History of pancreatitis or triglycerides &gt;=500 mg/dL Medullary carcinoma or multiple endocrine neoplasia (MEN2) or a family history of either Active cardiovascular disease Presence of congestive heart failure Liver disease History of severe gastrointestinal diseases Repeated severe hypoglycemia within the last 6 months Any previous use of exenatide or other glucagonlike peptide1 (GLP1 ) analog Dipeptidyl peptidase4 (DPP4) inhibitor use in the last 3 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>